Comparison · NCT02992743-a899e71f
Reduced Lymphodepletion Dose Plus GSK3377794 vs Standard Lymphodepletion Dose Plus GSK3377794: Number of Participants With Replication Competent Lentivirus (RCL)
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Reduced Lymphodepletion Dose Plus GSK3377794 vs Standard Lymphodepletion Dose Plus GSK3377794: Number of Participants With Replication Competent Lentivirus (RCL). Trial comparisons, record NCT02992743-a899e71f. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02992743-a899e71f
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0 | 0 | 0.278 | wilson | |
| Risk in group 2 | 0 | 0 | 0.324 | wilson | |
| Risk difference, group 1 minus group 2 | 0 | -0.324 | 0.278 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | log | a group has no participants with the outcome | |||
| Odds ratio, group 1 over group 2 | log | a cell of the two-by-two table is zero | |||
| Number needed to treat | from the risk difference interval | the two groups' risks are equal |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Reduced Lymphodepletion Dose Plus GSK3377794 | Eligible participants were leukapheresed to manufacture autologous NY-ESO-1c259 T cell receptors (TCR) bearing T-cells. Participants underwent lymphodepleting chemotherapy; cyclophosphamide 600 mg/m\^2/day plus fludarabine 30 mg/m\^2/day on day -7 through day -5 followed by a single infusion of GSK3377794 on Day 1. | 0 | 10 | OG000 |
| Group 2 | Standard Lymphodepletion Dose Plus GSK3377794 | Eligible participants were leukapheresed to manufacture autologous NY-ESO-1\^c259 TCR bearing T-cells. Participants underwent lymphodepleting chemotherapy consisting of cyclophosphamide 900 mg/m\^2/day starting on day -7 through day -5 plus fludarabine 30 mg/m\^2/day on day -8 through day -5 followed by a single infusion of GSK3377794 on Day 1. | 0 | 8 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Number of Participants With Replication Competent Lentivirus (RCL)
- Description
RCL was monitored using a polymerase chain reaction (PCR)-based assay that detects and measures copies of the gene coding for the vector's envelope protein, namely vesicular stomatitis virus G protein (VSV-G).
- Time frame
- Day 1 (pre-infusion), and at Week 12, Week 24, and 1 year post-infusion
- Population
Modified Intent-to-Treat (mITT) population which included all participants who underwent leukapheresis and received GSK3377794.. Only those participants with RCL assessed post T-cell infusion were included in the analysis.
Source ClinicalTrials.gov
Trial
- Title
- Letetresgene Autoleucel Engineered T Cells in NY-ESO-1 Positive Participants With Advanced Myxoid/ Round Cell Liposarcoma
- NCT number
- NCT02992743
- Phases
- PHASE2
- Conditions
- Neoplasms
- Interventions
- letetresgene autoleucel (GSK3377794), Cyclophosphamide, Fludarabine
- Lead sponsor
- GlaxoSmithKline
- Results first posted
- 2022-11-28
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02992743?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02992743-a899e71f